modelFatEmulsions
Extends from Pharmacolibrary.Drugs.ATC.B.B05BA02.
Information
| name: | FatEmulsions | |
| ATC code: | B05BA02 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 500 | mg |
| volume of distribution: | 0.15 | L |
| clearance: | 10 | mL/kg/min |
| other parameters in model implementation | ||
Fat emulsions are sterile preparations of oil-in-water emulsions, typically composed of purified soybean oil, medium-chain triglycerides, or other fats, stabilized by emulsifiers. They are predominantly used as a source of calories and essential fatty acids in parenteral nutrition for patients unable to intake food orally or enterally. Fat emulsions are approved and widely used in hospital settings for this purpose.
Pharmacokinetics
Estimated pharmacokinetic parameters for healthy adult individuals based on typical intravenous administration and general literature about parenteral fat emulsions. No definitive PK modeling publications found for specific formulation under ATC code B05BA02.
References
Kolnik, S, & Wood, TR (2022). Role of Vitamin E in Neonatal Neuroprotection: A Comprehensive Narrative Review. Life (Basel, Switzerland) 12(7) –. DOI:10.3390/life12071083 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35888171
Fukushima, K, et al., & Sugioka, N (2022). Individualization of the infusion rate of a soybean oil-based intravenous lipid emulsion for inpatients, based on baseline triglyceride concentrations: A population pharmacokinetic approach. JPEN. Journal of parenteral and enteral nutrition 46(1) 104–113. DOI:10.1002/jpen.2111 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33769561
Hoegberg, LC, et al., & Gosselin, S (2016). Systematic review of the effect of intravenous lipid emulsion therapy for local anesthetic toxicity. Clinical toxicology (Philadelphia, Pa.) 54(3) 167–193. DOI:10.3109/15563650.2015.1121270 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26853119
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)